Artivion (NYSE:AORT) SVP Jean Holloway Sells 6,393 Shares

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 6,393 shares of the company’s stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $45.00, for a total value of $287,685.00. Following the completion of the transaction, the senior vice president directly owned 163,408 shares in the company, valued at $7,353,360. This trade represents a 3.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Artivion Stock Down 0.6%

Artivion stock opened at $44.87 on Wednesday. The firm has a market cap of $2.13 billion, a price-to-earnings ratio of -106.83 and a beta of 1.65. The stock has a fifty day simple moving average of $42.77 and a two-hundred day simple moving average of $36.66. Artivion, Inc. has a 12 month low of $21.97 and a 12 month high of $48.04. The company has a current ratio of 4.78, a quick ratio of 3.48 and a debt-to-equity ratio of 0.52.

Artivion (NYSE:AORT) last announced its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.14 by $0.02. Artivion had a positive return on equity of 5.70% and a negative net margin of 4.43%.The firm had revenue of $113.39 million for the quarter, compared to the consensus estimate of $110.71 million. The firm’s revenue was up 18.9% on a year-over-year basis. Artivion has set its FY 2025 guidance at EPS. Equities analysts predict that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on AORT shares. Stifel Nicolaus raised their price target on shares of Artivion from $40.00 to $46.00 and gave the company a “buy” rating in a report on Monday, September 29th. LADENBURG THALM/SH SH downgraded shares of Artivion from a “buy” rating to a “neutral” rating and increased their price objective for the company from $32.00 to $38.80 in a research report on Wednesday, August 13th. JMP Securities raised their target price on shares of Artivion from $42.00 to $47.00 and gave the stock a “market outperform” rating in a report on Friday, October 10th. Citigroup reiterated an “outperform” rating on shares of Artivion in a research note on Friday, October 10th. Finally, Needham & Company LLC raised their price target on Artivion from $50.00 to $58.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $49.11.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the business. Aster Capital Management DIFC Ltd grew its position in shares of Artivion by 402.3% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares during the period. MCF Advisors LLC raised its holdings in Artivion by 109.3% in the 1st quarter. MCF Advisors LLC now owns 1,176 shares of the company’s stock worth $29,000 after purchasing an additional 614 shares during the period. Smartleaf Asset Management LLC lifted its position in Artivion by 47.7% during the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company’s stock valued at $52,000 after purchasing an additional 538 shares in the last quarter. State of Wyoming bought a new stake in Artivion during the third quarter valued at about $80,000. Finally, Quadrant Capital Group LLC bought a new stake in Artivion during the third quarter valued at about $92,000. 86.37% of the stock is currently owned by institutional investors.

About Artivion

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.